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Abstract
Background—The recent proliferation of studies describing factors associated with HPV
vaccine acceptability could inform health care providers in improving vaccine coverage and
support future research. This review examined measures of HPV and HPV-vaccine knowledge,
attitudes, beliefs and acceptability, described psychometric characteristics, and provided
recommendations about their use.
Methods—A systematic search of Medline, CINAHL, PsychoInfo, and ERIC through May 2008
for English language reports of quantitative data from parents, young adults or adolescents yielded
79 studies.
Results—The majority of studies were cross-sectional surveys (87%), self-administered (67%),
conducted before prophylactic vaccines were publicly available (67%) and utilized convenience
samples (65%). Most measured knowledge (80%), general attitudes about HPV vaccination
(40%), and willingness to vaccinate one's daughter (26%). Two thirds did not report reliability or
validity of measures. The majority did not specify a theoretical framework.
© 2010 Elsevier Ltd. All rights reserved
Corresponding Author: Jennifer Allen, DSc, MPH, Center for Community-Based Research Dana-Farber Cancer Institute 44 Binney
Street Boston, MA 02115 Tel: 617 632-2269 Fax: 617 632- 3161 jennifer_allen@dfci.harvard.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Disclaimer The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position
of the Centers for Disease Control and Prevention.
NIH Public Access
Author Manuscript
Vaccine. Author manuscript; available in PMC 2011 May 28.
Published in final edited form as:













Conclusions—Use of a theoretical framework, consistent labeling of constructs, more rigorous
validation of measures, and testing of measures in more diverse samples are needed to yield
measurement instruments that will produce findings to guide practitioners in developing
successful community and clinical interventions.
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INTRODUCTION
The recent availability of human papillomavirus (HPV) vaccines provides the potential for a
major step forward in reducing the public health burden of the most common sexually-
transmitted infection in the United States (U.S.). Yet, this will only occur if there is
widespread uptake of the vaccine. Behavioral interventions to ensure broad population
coverage require an understanding of vaccine acceptability and the factors that predict it.
Recently, there has been a proliferation of studies of this type. Several comprehensive
reviews have summarized findings from published studies [1–4]. Across studies involving
women, adolescents and parents, ratings of vaccine acceptability have generally been high.
Nevertheless, numerous studies document concerns regarding issues of vaccine safety [5–7],
efficacy [6–8], cost [9–13], and among parents, the potential impact of vaccination on
adolescent sexual behaviors [14–16]. Findings regarding other potential salient factors in
decision-making about vaccination, such as perceived severity and susceptibility to HPV
infection, have been inconsistent [1,17].
Existing reviews cite difficulties in cross-comparison of study findings due to differences in
study designs, sampling methods and populations, and in addition, differences in methods
for assessing constructs related to vaccine acceptability [1–4]. In particular, the lack of
standardized theoretical and operational definitions of constructs hypothesized to influence
vaccine uptake creates concern about use of available data to guide interventions. In the
absence of standardized methods for defining and measuring theoretical constructs, it is not
possible to know if inconsistent findings are the result of differences in measurement or true
variability across study populations. A high degree of measurement error could lead to
erroneous findings, leading researchers either to abandon a line of inquiry that is worthy of
further study, or to accept associations where none exist.
Given the early stage of this field and the rapid pace of new research, this is an opportune
time to evaluate measures of HPV vaccine acceptability and to consider next steps to
strengthen them. Thus, the aims of this paper are to: (1) systematically review measures
used in published studies of HPV vaccine knowledge, attitudes and behaviors; (2) describe
their characteristics and psychometric properties; and (3) provide recommendations to
improve the measurement of constructs in future studies.
METHODS
We sought primary reports that presented quantitative data of HPV and HPV-vaccine related
knowledge, attitudes, beliefs and acceptability. Studies included were those conducted in the
English language and that sampled parents, other young adults or adolescents in an
industrialized country. Qualitative studies, case reports, reviews, presentations of clinical
guidelines and studies of health care providers were excluded.
A trained health services librarian with experience in conducting and documenting searches
for systematic reviews searched the literature using Medline SilverPlatter, the Cumulative
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Index to Nursing and Allied Health Literature (CINAHL) SilverPlatter, PsychInfo CSA
(Cambridge Scientific Abstracts) ILLUMINA and Educational Resource Information Center
(ERIC). She selected the following search terms from Medical Subject Headings (MeSH):
human papilloma virus OR HPV AND vaccine AND accept*, aware*, attitude*, belief*,
behave*, decision, decide, intent*, know*, perceived*, percept*, risk*, sever*, uptake*, and
will*. Next, she examined the thesauri of the other databases to ensure consistency across
databases; adjustments were made as necessary to ensure standardization of search processes
across databases. Published reports from January 1995 to May 2008 were identified and
retrieved. Abstracts were reviewed for eligibility by three authors (JDA, MEF, RAT). When
additional information was needed to determine eligibility, the full-text article was retrieved
and reviewed.
A standardized data abstraction form was created based on a prior measurement review [18].
Coders (authors) abstracted information regarding study design, sample characteristics,
application of a theoretical framework, constructs assessed, and characteristics of measures
used to assess each construct. Determination of the constructs measured in each study was
based on the best match with construct definitions and examples of measures described in
authored papers posted by the Behavioral Research Program, Division of Cancer Control
and Population Sciences, National Cancer Institute on its website [19].
To ensure consistency in coding, a standardized codebook was created. As a next step, all
coders reviewed the same study and identified and resolved disagreements in coding. The
codebook was thereafter revised. For each study included in the review, two authors
independently coded and compared their results. Coding discrepancies within pairs were
resolved through discussion with all co-authors. Once initial coding was completed, all
authors reviewed the classification of measures for each of the constructs in each of the
papers, and discussed any disagreements until consensus was reached. We opted for this
group consensus method for coding, because of the large number of raters (eight) and the
enormous variability in terms of how constructs were described and defined across studies.
Data were entered into an online database; after cleaning, the data were downloaded into
Excel files and evidence tables were constructed, organized by major construct categories
(Table 1).
RESULTS
All citations (N=1052) were reviewed for eligibility based on titles and abstracts. Of these
367 required full-text reviews; 79 studies met inclusion criteria.
Study Characteristics
Most (87%) studies were cross-sectional, and approximately one-half were conducted in the
U.S. (Table 1). Two-thirds of U.S. studies and 36% of non-U.S. studies were conducted
prior to approval of the first vaccine (June 2006), which necessitated framing questions
about a hypothetical vaccine with unknown qualities that was not yet available. Most studies
recruited participants from health care facilities (42%) or colleges (30%). Over half of them
sampled women (58%). Almost two-thirds used samples of convenience; random sampling
was performed in 24% of studies. One third of studies included more than 75% white, non-
Hispanic participants. Sample sizes in most studies (88%) exceeded 100; 30% had samples
of 500 or more. The response rate was not reported or calculable in over 90% of all studies.
Of the small minority of studies (18%) that explicitly reported using an underlying
theoretical or conceptual framework—the most common were the Health Belief Model [20],
the Theory of Reasoned Action [21], or social cognitive theory [22].
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Few studies reported the sources of measures employed. When reported, measures were
generally described as having been developed by the authors. No studies that had adapted
measures from another source described the nature or extent of adaptation. Thirty percent of
the studies included reliability or validity information about the items that they used (see
Table 2). Internal reliability (Cronbach's alpha) was reported in 20% of studies [6,7,15,23–
36]. Test re-test reliability was reported in one study [31]. Weak tests of validity were
performed in 16% of the studies [5,8,23,24,26,29,30,34,37–39], primarily using expert
opinion or qualitative evaluation. Two studies used focus groups to improve the content
validity of survey items [8,15]; ten reported having had items reviewed by a panel of experts
or tested among similar populations [5,8,23,24,29,30,34,37–39]. Of the studies conducted in
the U.S., only one developed an instrument for Spanish-speaking populations [37].
Awareness and knowledge of HPV were by far the most frequently assessed constructs
(80% of studies), followed by attitudes toward vaccination (40%), willingness for one's
daughter to receive the vaccine (26%), willingness to receive the vaccine oneself (23%),
perceived vulnerability to HPV (21%), and perceived barriers to (16%) and benefits (15%)
of receiving the vaccine. Details are provided below.
Awareness and Knowledge of HPV and HPV vaccine
Awareness and Knowledge of HPV—Awareness of HPV was assessed in 31 (38%) of
the studies, usually as a single item, such as “Have you ever heard of the human
papillomavirus or HPV?” (Figure 1). Three-quarters of the studies assessed aspects of
knowledge, including the health consequences of HPV infection [5,8,10,15,23–29,37,40–73]
(typically cervical cancer and genital warts), modes of viral transmission [5,8,10,23,24,27–
32,37,40–43,45,46,49,50,52,54,55,57,63–65,68,72–75], and the asymptomatic nature of HPV
infection [5,23,25–29,37,40,45,46,48,54,56,57,63,65,68,69,73,75]. Studies with items addressing
knowledge of modes of viral transmission frequently assessed awareness that the virus is
sexually-transmitted; seven specifically measured awareness that both men and women can
acquire the virus [5,27,50,63,65,72,75]. Among studies assessing HPV health consequences,
some also asked whether participants endorsed health problems that are not associated with
HPV, such as infertility [23,49,50,54,68], or “myths” such as whether the virus can be
spread through toilet seats or by shaking hands with an infected person [24,27–29,42,62,64].
Nine studies [26–28,38,54,57,60,73,76] assessed some other aspect of HPV-related
knowledge, such as the relationship between HPV and other sexually transmitted diseases,
the need for continued Pap screening after vaccination, and the expected course of an HPV
infection. Some studies asked participants about their sources of information about HPV
infection, including where information was accessed and where they typically seek such
information [46,48,50,64,77,78]. Information about measures in a number of studies was
insufficient for us to determine which aspect of knowledge was assessed [6,9,33,79].
Awareness of the HPV vaccine was assessed in eight studies (10%), typically with a single
item such as, “Have you ever heard of the HPV vaccine?” [25,28,38,44,50,55,57,60]. Eight
studies assessed more in-depth aspects of knowledge about the vaccine
[5,8,33,38,44,47,50,77], including its efficacy [5,38,44].
Vaccine acceptability, intention and behavior
Vaccine acceptability—Items were categorized as “vaccine acceptability” if they
included the word “would,” as in “Would you agree to vaccination…” or “Would you accept
the vaccine…” Of 31 (39%) studies that measured this construct, 21 measured parental
acceptability of the vaccine for daughters [5,7,8,12,15,25,34,38,39,44,53,58,60,61,80–86].
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Eighteen measured acceptability for oneself [7,9,10,12,25,34–36,38,48,50,61,78,80,84,85,87,88],
and five inquired about the acceptability of vaccinating sons [60,61,74,80,84].
The majority of measures of acceptability for daughters (73%) were based on a single item,
such as, “How likely would you be to vaccinate your daughter for HPV?” Items in four
studies used an age referent [6,38,78,81]. Two studies that asked about vaccinating
daughters mentioned a cost condition, including “only if reimbursed” [38] and “willingness
to pay out of pocket” [25].
Vaccine acceptability for oneself was more often measured with multiple items (53%).
Response formats were typically Likert-type or dichotomous (32% and 26%, respectively).
Two studies assessed vaccine acceptability using a single cost referent “if it were free”
[25,34]. Two others assessed acceptability at graduated levels of cost [12,88].
A small number of studies inquired about acceptability (for self or daughter) of an HPV
vaccine that provided protection against different health outcomes, or had graduated levels
of efficacy [10,34,86,88]. For example, two studies by the same author [86,88] presented
hypothetical scenarios that varied along four dimensions (mode of transmission, severity of
infection, vaccine efficacy and availability of behavioral methods for prevention).
Participants rated the acceptability of each hypothetical vaccine. One assessed acceptability
of a free HPV vaccine that prevented either HPV, cervical cancer or genital warts [34].
Vaccine intentions is defined as the “the amount of effort one is willing to exert to attain a
goal” [89], “behavioral plans that…enable attainment of a behavioral goal” [21], or simply
“proximal goals” [22]. Intentions were assessed in six (7%) studies [6,31,33,54,55,74]; three
asked about intention to vaccinate a daughter [6,31,54,74] and three inquired about intention
to vaccinate oneself [33,54,55]. One study included assessment of intentions for self and
daughter [54], and one asked about both sons and daughters [74]. Item wording for intention
included, “I intend to have my daughter receive the HPV vaccine.” Only one study [33]
included a time frame for obtaining the vaccine (i.e., “in the next year”).
Vaccine uptake—Two studies assessed receipt of the HPV vaccine [33,48]. One included
a single item, “Have you received the HPV vaccine?” with no clarification regarding number
of doses [48]. In the other study [33], the item asked if the participant had received “at least
one” dose of the HPV vaccine.
Vaccine attitudes and beliefs
Perceived severity of HPV reflects the “perception of negative consequences associated with
an event or outcome” and is generally assessed by asking respondents to rate their
agreement with the following question: “I believe that [HPV infection] is…`severe' or
`serious' or `significant.' [19]. This construct was assessed in 14 studies (18%)
[6,7,9,15,24,25,29,32,33,35,48,57,77].
Items generally asked how upsetting or disruptive a diagnosis of HPV would be in terms of
one's physical health, social relationships, or in finding a “long term sexual partner”
[7,9,35], whether there are medical complications of HPV infection [29], and whether HPV
can be cured [24], or is life-threatening [24]. Some studies asked about shame associated
with a diagnosis of HPV [6,32,35,48,90]. The referent in most of these studies was oneself;
in one study it was also a partner [57], and in another, the respondent's children [6]. Three
studies did not report specific wording [15,25,33]. Of the studies that assessed perceived
severity of HPV, two also assessed perceived severity of cervical cancer [24,25]. One study
assessed perceived severity of genital warts [77].
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Perceived vulnerability to HPV is defined as the perceived likelihood of developing a health
problem and is often assessed by asking “How likely is it you will get [HPV]” [19]. Items
that address conditional perceived susceptibility typically ask about the likelihood of an
event given that an action is/is not taken (e.g., “What would be the likelihood of getting
[HPV] if you [did X]“), and items that address comparative perceived susceptibility
typically ask “Compared to others your age, how likely is it you will get [HPV].” Perceived
susceptibility was measured in 22 studies (28%); of these, 17 had items referring to
susceptibility of oneself [7,9,10,24,25,27,29,33,35,42,47,48,51,54,57,85,91] and five had items
referring to susceptibility of a daughter [6,15,25,39,85]. General perceived susceptibility
items asked respondents to rate their own or their daughter's chances of having HPV or
getting it in the future [6,9,15,35,39,42,57], or ability to avoid contracting it in the future
[24]. One study addressed conditional perceived susceptibility, asking whether one's risk
would be increased with riskier sexual activities [91]. Of the studies that assessed perceived
vulnerability to HPV, three also assessed perceived vulnerability to cervical cancer in
reference both to themselves [19,24,25,54] and to their daughters [25].
Perceived benefits of the vaccine, defined as opinions about positive consequences of
adopting a behavior [19], were assessed in 12 studies (15%). Nearly one-half asked about
general benefits, [6,25,31,44,58] while others included more specific benefits, such as
whether the HPV vaccine would help an individual to stay healthy [7,10,35], provide health
benefits for oneself or one's partner [33,35], including protecting against future HPV
infection [54], or preventing cervical cancer [10,50,54], genital warts [8,10,50], or penile
cancer [8]. One study [10] also explored the extent to which being a role model for one's
children was perceived as a benefit of vaccination.
Perceived barriers, defined as opinions about logistical or psychological costs of engaging in
a behavior [19], were assessed in 13 studies [7,9,10,12,15,25,33,35,38,53,54,61,77]. These
items differed from those under the “willingness to vaccinate” construct conditioned on cost
(discussed above), as they did not assess cost in relation to acceptability or intentions. Cost
items directly asked whether cost was a barrier [10,12,53], the importance of the vaccine
being free or low cost [9,25,38,54], or inquired about impact of health insurance coverage of
the vaccine [7,77]. Other items assessed the impact of beliefs that getting “shots” would be
difficult or painful [9,33,54]. Some assessed lack of knowledge about HPV or the vaccine as
a barrier [33,61]. A few studies focused on ease of getting to a provider [25] or difficulty
obtaining the vaccine [33,35].
Thirteen (16%) studies assessed perceived risks associated with the vaccine as a potential
barrier by assessing general harmfulness of the vaccine [5,7–9,15,33,38,44,54,55], or
concern about getting HPV from the vaccine itself [8,10] Others assessed specific risks, such
as short-term or long-term side effects [5,15,44,83], effects on adolescent development [5],
and concerns about giving children too many vaccines [15,61,83]. Other risks included
concerns about the vaccine influencing sexual behavior, for example, the extent to which
vaccination would encourage earlier age at sexual debut [8,12,15,44], diminish incentives
for having safe sex [15,31], and promote acceptance of having more sexual partners [15,31].
Perceptions of who should receive vaccine—Seven studies (9%) inquired about the
appropriate recipients of the vaccine (e.g., different age groups of girls)
[5,9,12,38,54,61,78]. Some asked about vaccinating children before they become sexually
active [5,12,54]. Five studies also measured agreement with vaccinating males
[12,38,54,61,78] and two assessed attitudes toward vaccinating boys and girls [12,61].
Perceived effectiveness of the vaccine was evaluated in eight studies (10%)
[5,7,8,12,25,31,39,54]. Typically, effectiveness was assessed in terms of protection from
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cervical cancer [5,8,12,25,31,39,54] or from specific types of HPV [5,7,8,25,54]. One [8]
also asked about vaccine efficacy against penile cancer and genital warts.
Among other HPV attitudes and beliefs assessed were: perceived behavioral control in
having a child vaccinated [31]; self-efficacy with regard to getting the vaccine once it
became available [35] or ability to complete the three dose series [33]. Several other studies
generally assessed the “importance” of the HPV vaccine [9,10,39,83].
Social Influences
Subjective norms, as defined by the Theory of Reasoned Action, reflects normative beliefs,
the perceptions of salient others' (e.g. spouse, friends) support for or opposition to a
behavioral action, weighted by motivation to comply [92]. Typically, assessment of this
construct involves pairs of questions. The first question assesses the respondent's perception
of important others' attitudes toward a specified behavior. The second question then inquires
about the degree to which important others' opinions influence the respondent's decision.
The product of the question pairs (support multiplied by motivation to comply) reflects the
full construct [19]. In this review, both aspects of subjective norms were measured in four
studies [7,31,55,74]. Four studies measured normative beliefs only [9,15,33,54], and three
studies measured motivation to comply [6,39,47], sometimes framed as a `cue to action.'
Descriptive social norms, for the purposes of this paper, were defined as “an individual's
perceptions about the acceptability of a behavior” derived from communications from
network members or by portrayals of behavior in the mass media [19]. Social norms were
measured in two studies [15,55]. Another form of social influence, provider
recommendation of vaccination, was measured in ten studies [6,7,9,12,15,25,36,39,47,54].
These generally asked, “Has your health care provider recommended the HPV vaccine [for
you/for your daughter]?”
Conclusions
We believe this to be the first systematic review of measurement instruments used in
published studies to assess knowledge, attitudes and beliefs, and behaviors regarding the
HPV vaccine. In a prior review, Tiro and others [68] examined items used to measure
vaccine behaviors in national surveillance programs. Other reviews [1,3] have synthesized
findings of studies addressing HPV knowledge and attitudes or beliefs about the HPV
vaccine. The existing body of literature on HPV vaccine acceptability has identified a
variety of individual and social factors that may impact uptake. These studies represent a
beginning from which future inquiries will benefit. Yet there remains a need for validated
measures in the field. Accurate measurement tools are critical for the identification of
accurate and salient factors associated with vaccination. Data from such measures is critical
to the development of evidence-based interventions to ensure widespread uptake of the
vaccine.
In our review, we found that the bulk of research has focused on awareness and knowledge
about HPV. This is not surprising, because the causal relationship between HPV and
cervical cancer is a relatively recent discovery, HPV vaccines have only been available for a
short time, and the field is in an early stage of development [93]. At least two-thirds of
existing U.S. studies and 36% of non-U.S. studies in this review were conducted prior to
vaccine licensure. In these studies, questions related to vaccine attitudes and behaviors were
framed in hypothetical terms (e.g., “If there were a vaccine available…”) out of necessity.
However, there is evidence to suggest that, under circumstances where benefits and potential
harms are unknown-- such as in the case with a hypothetical vaccine scenario-- reported
intention is not highly correlated with actual participation. For example, self-reported
Allen et al. Page 7













intention to participate in clinical trials is considerably lower than actual participation
[94,95]. On a related note, some studies asked about willingness to vaccinate a child if the
respondent were to have one (i.e., hypothetical child). The validity of using instruments and
comparing findings from inquiries of hypothetical versus actual vaccines and hypothetical
versus actual daughters is unknown. However, one study [38] reported findings from
surveys conducted among adults, some of whom had daughters and/or sons and some of
whom did not. With respect to willingness to vaccinate a daughter or son, notable
differences were observed in responses from parents and non-parents. Specifically, those
with children had higher levels of willingness to vaccine them. This suggests that caution
should be used when interpreting results from such studies.
We observed inconsistency between authors' labels for what they were measuring and the
theory-based definitions endorsed by the National Cancer Institute [19]. Many authors used
the same measures to assess constructs that they variously called “vaccine intentions” and
“vaccine acceptability.” In addition, we noted a problem with conceptual overlap among
constructs included in this review. Some studies combined items that addressed multiple
constructs to form a single scale. The mixing of constructs within a single scale, and the
overlap of items measuring disparate constructs can increase measurement error and
diminished ability to compare findings across studies. Moreover, it diminishes the
interpretability of psychometric properties of measures.
Of concern is that nearly 70% of the studies reported no information about reliability. Most
frequently, internal consistency reliability (Cronbach's alpha) was the only attribute
reported. This can be calculated following data collection, but it is a relatively weak
indicator of measure quality. Reports of Cronbach's alpha were almost exclusively for
knowledge scales, and they generally demonstrated adequate consistency, meaning that the
items were measuring a single unidimensional latent construct. It does not mean that that
they were measuring the construct they intended to measure, however, as we discuss below.
A more important assessment would be stability of ratings over time, yet only one study
assessed test-retest reliability [24].
Assessment of any form of validity was rare; only 16% of studies reported any information
about this property. Content validity, assessed through expert opinion, was reported for
some measures; other investigators pilot-tested instruments among individuals with similar
demographic characteristics as their target audience. Yet, stronger forms of validation,
including criterion and discriminant validity, were not reported for any of the measures in
this review. In most cases, authors either developed items or adapted them from published
research. This is understandable, given that there are not many existing measures
specifically developed for HPV vaccination. However, reports provided little or no
information about how they developed or adapted items, information that is considered
essential in reporting guidelines [96–99]. Of great concern is that a substantial number of
studies used single items to assess relatively complex constructs, which makes it unlikely
that these measures fully represented the intended construct. As such, information to guide
investigators seeking to identify standardized measures or those with documented
psychometric qualities for future research is limited.
The absence of information about potential cultural influences on HPV vaccine behaviors is
also particularly notable, since these factors could play a crucial role in the development of
vaccine intervention messages or the selection of channels of intervention delivery. A large
portion of studies were conducted among college students and predominantly non-Hispanic
White samples with relatively high levels of education. Black individuals represented one-
quarter or more of the samples in only five studies [8,25,33,34,37]. And, few studies
included meaningful numbers of Latinas, women in rural locations, and those with lower
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levels of income and education [100], although these groups are disproportionately affected
by HPV-associated illnesses. Among the articles we reviewed, only one reported developing
a survey in both English and Spanish [37]. No studies reported the literacy level required to
read the measures. The historically low uptake of vaccines in high risk populations warrants
a concentrated effort toward the development of measures that will provide the necessary
data to develop culturally relevant and linguistically appropriate interventions.
Recommendations
We offer several recommendations about development and reporting of measures, in hopes
of motivating efforts toward the development and use of standardized measures with
demonstrated validity and reliability. We begin with recommendations that are applicable to
measurement of any study topic, then address some of the unique challenges of measuring
acceptability and uptake of a new vaccine for a sexually transmitted disease.
As this field of research advances, it is critical that increased attention be focused on the
development of measures so as to improve our understanding of factors that influence
vaccine uptake. One step toward this goal would be greater use and explication of
conceptual underpinnings of studies. Theory provides conceptual clarity for construct
definitions, guides the designation of primary and secondary outcomes, can identify
potential mediating and moderating factors, determine the timing of data collection, and
dictate analytic strategies. Greater use of standardized construct definitions, for example as
provided by the NCI website, would facilitate consistent measurement and enable greater
comparability of findings across studies. The majority of theory-based studies included in
this review applied the Health Belief Model and Theory of Reasoned Action, which focus
heavily on the influence of individual perceptions and behavior. We advocate use of a
conceptual framework that also considers the influence of interpersonal relationships,
institutional and health-system factors, mass media, as well as vaccine policy [101]. For this,
an ecological model, such as that described by McElroy and colleagues [102], can facilitate
a more comprehensive understanding of vaccine attitudes and behaviors in a broader context
[101]. Moreover, it may be useful to draw from theories of informed decision making, such
as those developed by O'Connor [103], as well as decision sciences [104].
As noted, the majority of studies to date focused on HPV knowledge. As knowledge levels
increase over time and with greater exposure to information about the vaccine [3], additional
emphasis on attitudes and beliefs is warranted, particularly because knowledge is a weak
predictor of behavior [105]. While it is likely that intervention efforts will likely focus on
disseminating knowledge, we recommend additional study of the specific domains of
knowledge required for informed decision-making, such as vaccine risks, benefits,
limitations, as well as predicted efficacy and duration of effect.
Exploration of other constructs, such as intention and actual behavior, will also be
increasingly important as awareness of HPV and the vaccine increases. As time passes, it
will be critical to measure compliance with the three-dose series and with cervical cancer
screening recommendations, particularly among groups that suffer a disproportionate burden
of HPV-associated illness. In addition, studies are needed to better understand provider
knowledge and behaviors. Much attention has focused on individual or parental
characteristics that influence decisions to vaccinate. However, if a provider does not
recommend vaccination, individual and parental decisions may be inconsequential. It will
also be important to understand the impact of direct-to-consumer advertising, extensive
media attention, and controversial legislative efforts to mandate vaccine coverage on HPV-
related attitudes and behaviors. While study of HPV vaccine uptake presents unique
challenges given this context, studies of uptake of the Hepatitis B vaccine [106,107] and
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acceptability of future HIV vaccines [108,109] share similarities (e.g., sexual transmission)
and could provide insights for the development of standardized measurements.
When necessary to develop original measures, review of items by a panel of experts [110],
cognitive interviewing [111], and pilot testing of items among the intended audience [110] is
recommended to optimize content validity, minimize “floor” or “ceiling” effects, and to
improve understandability. Such efforts to develop questions to assess theoretically-derived
constructs associated with HPV vaccine uptake are currently underway [112]. In addition,
because HPV is a sexually-transmitted virus and some parents are concerned that
vaccination may result in unsafe sexual behaviors, sensitivity is also needed in the
development of items to assess vaccine decisions. To reduce the potential for social
desirability bias or underreporting, questions should be constructed with neutral wording,
could incorporate question stems that indicate researcher impartiality (e.g., “Many people
believe that there are advantages and disadvantages to HPV vaccination”), or might utilize
open-ended response options (e.g., “What are your concerns about vaccinating your
daughter?”) [110].
Overall, inclusion of more detail about measures in study reports such as information about
methods used to develop measures, changes made to existing measures if used, as well as
strategies employed to assess validity and reliability would facilitate methodologic
advancements. Reporting standards, CONSORT (Consolidated Standards of Reporting
Trials) [96,97], TREND (Transparent Reporting of Evaluations with Non-Randomized
Designs) [98], and STROBE [99] provide detailed guidance for reporting important details
about study methods and results for the respective types of study they address. Greater
consideration and use of these guidelines would ensure the availability of information
needed to assess strengths and limitations of research in this field. Moreover, establishing a
central repository for measures would aid investigators in identifying tested items, the use of
which would facilitate cross-comparison of study findings. Agencies funding such research
ought to collaborate to create this repository and consider requiring this sharing function for
newly funded research.
We also recommend more attention to the development and testing of measures for high-
priority audiences. While women in the HPV vaccine “catch-up” age group (i.e., 13–26
years of age) are currently an important target audience, parents will likely be the primary
audience at whom future vaccination efforts are directed, particularly those who are
members of `minority' racial and ethnic groups, individuals with low literacy skills, and non-
English speakers. These groups experience disparities to access of health information and
may also have diminished access to vaccine [113]. Notably, rates of initial vaccination
appear to be higher among those with lower levels of income and education, as well as
Hispanics [114]. This may be due to reduced financial barriers to the vaccine because of the
federal Vaccine for Children Program, which makes vaccine available free-of-cost.
Nevertheless, we believe that these groups remain a high priority for intervention efforts
because of diminished access to information about the vaccine [113], lower rates of
completion of the three-dose series [115], and unremitting disparities in cervical cancer
incidence and mortality [116]. Development of valid and reliable instruments to assess
knowledge, attitudes and behaviors across audiences that are diverse with respect to race/
ethnicity, language, literacy levels-- as well as gender [117] now that the vaccine is available
to boys-- will require time, resources, and a concerted effort among investigators. In the
meantime, giving research consumers sufficient information with which to assess the quality
of measures is essential for judicious application of study findings.
Evidence-based interventions for HPV vaccination are needed. Such interventions will be
guided by the literature on factors associated with vaccine intentions and acceptability.
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While the currently-available literature provides the preliminary foundation from which to
launch such efforts, additional development of measures to assess factors that influence
vaccine decision-making is needed to further advance this goal.
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Table 1
Characteristics of the 79 Included Studies
n %
Study design
Randomized controlled trial 3 4






Not specified 2 3
Study setting*
Population-based setting 26 33
Health care setting 33 42
School setting 7 9
College setting 24 30
Other 6 8
Data collection method
Self-administered survey 53 67
Interviewer-administered survey 20 25






Women and men 14 18
Adolescent girls (<18) 22 28






























Pre vaccine licensure 53 67
Post vaccine licensure 13 17
Not stated 14 18
Note. Some categories are not mutually exclusive, as some studies were conducted in multiple settings or with multiple sample types or theoretical
models.
*
Non-US countries were Australia (5 studies); Belgium (3); Brazil (2); Canada (n=4); Columbia (n=1); Finland (n=1); Germany (n=1): Hong Kong
(n=2); Iceland (n=1); Mexico (n=2); Netherlands (n=1); Sweden (n=1); Turkey (n=1); UK (n=10); and Vietnam (n=1).
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Table 2
Characteristics of 25 studies that reported reliability or validity information
Study Construct (number of items in
measure)*
Reliability Validity Sample Characteristics
Benning, 2007[37] HPV Awareness (1); know-ledge
of HPV health conse-quences (4),
transmission (5), symptoms (2),







363 women age 15–74
(mean=29); 41% White, 28%
Black, 24% Hispanic, 3% Asian,
2% Other
Bertram, 2008[23] Knowledge HPV health
consequences (3), transmission (1),
symptoms (2), DNA test (2),











492 college students, 75%
female; 49% Asian, 19% White,
12% Filipino, 11% Hawaiian, 4%
Hispanic
Brabin 2006[5] Knowledge HPV health
consequences (3), transmission (3),
symptoms (1), risk factors (1),
treatment (1), vaccine efficacy (1);
acceptability daughter (1),
perceived risk (3) and perceived
efficacy (4) of the vaccine
Not reported Three rounds of
validation (method
not reported)
317 parents of 11–12 yr olds;
72% parents of girls; 65% White,
17% Black, 12% Indian, 4%
Other, 2%
Davis 2004[8] Knowledge HPV health
consequences (5), transmission
(NR), treatment (1), other/
unspecified knowledge of HPV (1)
and HPV vaccine (NR);
acceptability-daughter (1);
perceived benefits, (2) perceived
risk, and perceived efficacy (5) of
the vaccine (3); general beliefs /
attitudes (11)
Not reported 2 rounds of pilot
testing with focus
group of 7 parents
of 10–15 year old
girls
506 parents of 10–15 year olds,
89% female, 51% White, 45%
Black, 4% Other
Dempsey2006[6] Intention (daughter) (3) α=0.83 Not reported 840 Parents/primary caregivers of
8–12 year olds, 84% female,
ethnically, culturally, over 25
racial/ethnic groups, 75% White,
5% Black, 11% Asian, 9% other
or unreported (baseline survey
participants); 78% White, 4%
Black, 11% Asian, 7% other or
unreported (information sheet
participants)
Perceived benefits (3) and barriers
(3); susceptibility (daughter) (3);
general beliefs /attitudes (3)
α=0.68–0.78
Perceived severity (3); subjective
norms (2); normative beliefs (1)
α=0.20–0.27
Denney-Smith, 2006[24] Knowledge HPV health
consequences (3) and transmission
(1); perceived severity (2) and
susceptibility (self) (5); general























240 female nursing students aged
19–58
Dinh, 2007[39] Awareness of HPV (1);
acceptability-daughter (1);
perceived susceptibility-daughter
(1); perceived efficacy (1); general
beliefs / attitudes (1)





181 Vietnamese mothers of 10–
18 year old girls, age range 26–
60, mean age 42
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Study Construct (number of items in
measure)*
Reliability Validity Sample Characteristics
clarity in content,
context, and tone
Donders, 2008[38] Awareness of HPV vaccine (1);
knowledge HPV other (1), other/
unspecified knowledge of HPV
vaccine (1); acceptability-daughter
(1), acceptability-self (2);
perceived barriers (3), risk of the
vaccine (2); perceptions re: who
should get the vaccine (3)
Not reported Questions were





372 women, mean age 36, 79%
parents, 51% parents of daughters
Fazekas, 2008[25] Acceptability-daughter (3), self (3) α=0.89 Not reported 146 rural women, mean age 42,
62% Black, 32% white, 2% other,
4% unreported, 85% mothersPerceived benefits (6) α=0.7–0.94
Perceived barriers (3) α=0.79
Gerend, 2007[36] Acceptability-(self (5) α=0.96 Not reported 121 female college students age
18–25 (mean age 19), 85%
White, 10% Black, 5%
unreported, (12% of Whites
reported Hispanic ethnicity)
Gerend, 2007[7] Acceptability-(self (4) α=0.90 Not reported 58 women 1–50, mean age 26,
29% White, 59% Black, 12%
other
Gerend, 2008[35] Acceptability-self (5) α=0.97 Not reported 237 female college students age
18–26, mean age 19, 76% White,
13% Black, 2% Asian, 9% mixed
or other (8% of Whites reported
Hispanic ethnicity)
General beliefs / attitudes (2) α=0.94
Perceived severity (4) α=0.90
Perceived susceptibility-self (2) α=0.94
Perceived benefits (3) α=0.86
Perceived barriers (2) α=0.90
Holcomb20 04[26] Knowledge of HPV health
consequences (5)







288 men and women from under
20 to over 46, sample primarily
female and White; 77% White,
14% Black, 2% Hispanic, 3%
Asian, 1% other, 3% unreported
(Family practice sample); 64%
White, 9% Black, 7% Hispanic,
13% Asian, 1% other, 6%
unreported (Student health clinic
sample)
Knowledge of HPV risk factors
(14)
α=0.93
Knowledge of HPV symptoms (1) α=0.92
Kahn, 2008[33] Intention to receive vaccine -self-
(1)
α=0.82 Not reported 409 women aged 13–26, mean
age 19, 29% White, 60% Black,
9% other, 2% unreported
General beliefs and attitudes (28) α=0.79–0.96
Perceived severity of HPV (5) α=0.75–0.76
Perceived susceptibility to HPV-
self (2)
α=0.77
Perceived benefits of vaccine (6) α=0.65–0.82
Perceived barriers to vaccine (11) α=0.66–0.82
Perceived risk of vaccine (4) α=0.82
Marlow, 2007[15] Awareness of HPV (1);
acceptability of vaccine-daughter
(1), perceived barriers (2) and
perceived risk of the vaccine (2);
general beliefs and attitudes (NR);
social norms (NR)
Not reported Pilot focus groups 680 mothers of 8–4 y.o. girls,
mean age 41, 92.6% White
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Study Construct (number of items in
measure)*
Reliability Validity Sample Characteristics
Marlow, 2007[83] General beliefs and attitudes (NR) α=0.66–0.76 Not reported 684 mothers of at least 1 daughter
age 8–14, mean age 41, 93%
White
Moreira, 2006[30] Knowledge of HPV health
consequences (1), transmission (1),
other knowledge (1); general
beliefs / attitudes (NR)
Not reported Face validation
assessed by health
survey experts
204 women age 16–23, mean age
20, 2% White, 26% Black, 72%
mixed ethnicity
Ogilvie, 2007[31] Awareness of HPV (1); knowledge
of HPV transmission (1); perceived
benefits (2), risk of the (2), efficacy
of vaccine (2); general beliefs /
attitudes; subjective norms (5)
α≥0.60 Not reported 2083 parents of children aged 8–
18, 74% female, age range: 19–
>60, 83% White, 2% Aboriginal,
15% other, 65% had daughters
Ogilvie, 2008[74] Awareness of HPV (2); knowledge
of HPV transmission (2)
α=0.60 Not reported 2083 parents of children aged 8–
18, 74% female, age range: 19–
>60, 83% White
Ramirez, 1997[27] Other knowledge (20) α=0.60 Not reported 110 female college students 18–
22, mean age 20, 54% White, 6%
Black, 23% Asian, 13%
Hispanic, 6% Other
General beliefs and attitudes (NR) α=0.89







146 women 18–84 (mean age
42), 32% White, 62% Black, 6%
other, 62% had daughters, 19%
had daughters 11–16
Waller, 2007[32] General beliefs / attitudes (17) α=0.73–.90 Pilot testing 811 female college students 18–
30, 68% White, 2% Black, 20%
Asian, 10% Other
Wang, 2006[28] Knowledge of HPV transmission
(10), symptoms (6), and other
knowledge (30)
α=0.77 Not reported 159 rural female high school
students 14–20 (mean age 17),
98% White





289 college students, median age
25, 63% female, 81% White, 5%
Black, 7% Hispanic, 7% Other
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